NOVEL AAV'S AND USES THEREOF

• US 20140296486A1
• Filed: 04/07/2014
• Published: 10/02/2014
• Est. Priority Date: 05/28/2009
• Status: Active Grant

• Current Assignee: University Of Massachusetts
• Original Assignee: University Of Massachusetts
• Inventors: Gao, Guangping, Flotte, Terence, Xie, Jun
• Granted Patent: US 9,284,357 B2
• Time in Patent Office: Days
• US Class Current: 530/350
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 35/76 Viruses; Subviral particles; Bacteriophages
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2750/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/14145 Special targeting system for viral vectors
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

Claims

1-48. -48. (canceled)

49. An isolated adeno-associated virus (AAV) capsid protein of a serotype selected from a member of the group consisting of AAV6, AAV9 and AAV2.

50. The isolated adeno-associated virus (AAV) capsid protein of claim 49, which is an AAV6 serotype and comprises the amino acid sequence of a member of the group consisting of SEQ ID NO:

151-159.

51. The isolated adeno-associated virus (AAV) capsid protein of claim 49, which is an AAV9 serotype and comprises the amino acid sequence of a member of the group consisting of SEQ ID NO:

87-102, 104-128.

52. The isolated adeno-associated virus (AAV) capsid protein of claim 51, comprising the amino acid sequence of a member of the group consisting of SEQ ID NO:

87-95.

53. The isolated adeno-associated virus (AAV) capsid protein of claim 51, comprising the amino acid sequence of a member of the group consisting of SEQ ID NO:

96-102, 104-112.

54. The isolated adeno-associated virus (AAV) capsid protein of claim 51, comprising the amino acid sequence of a member of the group consisting of SEQ ID NO:

113-118.

55. The isolated adeno-associated virus (AAV) capsid protein of claim 51, comprising the amino acid sequence of a member of the group consisting of SEQ ID NO:

119-128.

56. The isolated adeno-associated virus (AAV) capsid protein of claim 49, which is an AAV2 serotype and comprises the amino acid sequence of SEQ ID NO:

160.